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Abstract
Background: Aberrant promoter DNA methylation has been shown to play a role in acute myeloid leukemia (AML)
pathophysiology. However, further studies to discuss the prognostic value and the relationship of the epigenetic signatures
with defined genomic rearrangements in acute myeloid leukemia are required.
Methodology/Principal Findings: We carried out high-throughput methylation profiling on 116 de novo AML cases and we
validated the significant biomarkers in an independent cohort of 244 AML cases. Methylation signatures were associated
with the presence of a specific cytogenetic status. In normal karyotype cases, aberrant methylation of the promoter of DBC1
was validated as a predictor of the disease-free and overall survival. Furthermore, DBC1 expression was significantly silenced
in the aberrantly methylated samples. Patients with chromosome rearrangements showed distinct methylation signatures.
To establish the role of fusion proteins in the epigenetic profiles, 20 additional samples of human hematopoietic stem/
progenitor cells (HSPC) transduced with common fusion genes were studied and compared with patient samples carrying
the same rearrangements. The presence of MLL rearrangements in HSPC induced the methylation profile observed in the
MLL-positive primary samples. In contrast, fusion genes such as AML1/ETO or CBFB/MYH11 failed to reproduce the
epigenetic signature observed in the patients.
Conclusions/Significance: Our study provides a comprehensive epigenetic profiling of AML, identifies new clinical markers
for cases with a normal karyotype, and reveals relevant biological information related to the role of fusion proteins on the
methylation signature.
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Introduction
Acute myeloid leukemia (AML) is the most common type of
acute leukemia in adults. Chemotherapy induces complete
remission in 70 to 80 percent of patients, but half relapse and
die. Therefore, accurate predictors of clinical outcome can
contribute to the design of appropriate treatment for individual
patients. Cytogenetic and molecular markers are currently the
most powerful prognostic factors. The karyotype is used to classify
patients as being at low, intermediate, or high risk. Nevertheless,
there is substantial heterogeneity within each risk group. Thirty-
five to 50 percent of patients have a normal karyotype, and
molecular markers, such as mutations in FLT3, CEBPa, and
NMP1, further stratify this large group. These prognostic markers
are non-random irreversible genetic aberrations that activate
oncogenes, inactivate tumor suppressor genes, and form novel
chimeric genes that lead cells to progress to the malignant
phenotype [1,2].
There is increasing evidence that, in addition to genetic
aberrations, therapeutically reversible epigenetic events play a
critical role in the pathogenesis of human cancer [3,4]. Methylation
of the cytosines at the palindromic CpG sites clustered in gene
promoter regions plays an important role in the epigenetic silencing
of genes such as ESR1, IGSF4, and CDKN2B/p15 during the
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more, recent data suggest that promoter DNA methylation patterns
could provide important additional information regarding risk and
outcome [8,9,10]. However, the prognostic value of individual
DNA methylation biomarkers, on the context of specific cytogenetic
subgroups has not been evaluated.
From the biological standpoint, genome AML-associated fusion
proteins that result from chromosome translocations have been
reported to help establish specific DNA methylation patterns in
AML. For example, PML/RARa and AML1/ETO have been
shown to recruit both histone deacetylases and DNA methyltrans-
ferases to induce transcriptional repression of target genes [11],
and abundant epigenetic lesions have been identified along with
recurrent chromosome translocations such as t(8;21), t(15;17) and
Inv(16) [8,9]. Although these data support the idea of a link
between epigenetic and genetic changes, the contribution of the
fusion proteins to the aberrant DNA methylation signature need to
be better established.
Here we report a detailed comprehensive methylation profile to
systematically explore the epigenomic variation underlying AML.
The findings were correlated with clinical outcomes, and the
contribution of different chromosomal rearrangements to the
methylation profile was determined.
Materials and Methods
Samples
Two series of patients diagnosed with de novo AML were
studied. An original series of 116 cases was analyzed. DNA was
collected in all instances from the leftover biological material after
a proper diagnosis was achieved at the cytogenetic laboratories of
the Universidad de Navarra (Pamplona, Spain), the Spanish
National Cancer Center (CNIO, Madrid, Spain), and the
Christian-Albrechts University (Kiel, Germany) (Table 1). The
Spanish patients were treated according to the PETHEMA
LAM99 clinical protocol [12]. The control samples comprised 4
bone marrow specimens and 2 CD34+ selections from the
mobilized peripheral blood stem cells of healthy donors. An
independent validation series of 244 cases was collected from
Hospital la Fe (Valencia, Spain) and Hospital Reina Sofı ´a
(Co ´rdoba, Spain). Thirteen cases of primary acute lymphoblastic
leukemia (ALL) were also included. All samples were analyzed
anonymously.
We analyzed DNA from 25 primary human hematopoietic stem
cells/progenitor cells (HSPC) taken from cord blood samples.
Human umbilical CB was obtained by the Translational Trials
Support Laboratory at CCHMC under a protocol approved by
the CCHMC Institutional Review Board. No identifying infor-
mation related to the infant or mother was obtained with these
collections. These HSPC were stably transduced with retroviruses
expressing different fusion proteins or with an empty vector and
cultured for 12 to 17 weeks. This model have been studied in
depth elsewhere [13].
Methylation profiling
All samples were processed at CNIO. Microarray-based DNA
methylation profiles were obtained using the GoldenGate
Methylation Cancer Panel I (Illumina, Inc., San Diego, CA,
USA). The panel contains 1505 CpG sites selected from 807
genes, including oncogenes and tumor suppressor genes, imprinted
genes, genes involved in various signaling pathways, and genes
responsible for DNA repair, cell cycle control, metastasis,
differentiation, and apoptosis.
The methylation assay was performed as described previously
[14]. Briefly, for each CpG site, four probes were designed—two
allele-specific oligos (ASO) and two locus-specific oligos (LSO).
Each ASO-LSO pair corresponded to either the methylated or
unmethylated state of the CpG site. Bisulfite conversion of DNA
samples was performed using the EZ DNA methylation kit (Zymo
Research, Orange, CA, USA). The remaining assay steps were
Table 1. Summary of clinical data and distribution according
to the DNA methylation profile.
Cluster
Group I Group II
Gender
Male 63 31 32
Female 53 27 26
Age
,60 yr 31 15 16
.60yr 85 43 42
FAB Sub-type p*=0.011
M0 4 3(75%) 1(25%)
M1 19 13(68%) 6(32%)
M2 30 16(53%) 14(47%)
M3 9 0(0%) 9(100%)
M4 13 8(61%) 5(39%)
M4EO 11 5(45%) 6(55%)
M5 27 10(37%) 17(63%)
M6 3 3(100%) 0(0%)
TOTAL 116 58(50%) 58(50%)
Cytogenetic Prognosis Group** p*,0.001
Favorable 30 6(20%) 24(80%)
t(8;21) 10 1(10%) 9(90%)
inv(16) 11 5(45%) 6(55%)
t(15;17) 9 0(0%) 9(100%)
Intermediate 61 32(52%) 29(48%)
Normal Karyotype 41 23(56%) 18(44%)
Single Trisomy 12 5(42%) 7(68%)
Double Trisomy 3 2(67%) 1(33%)
Other Intermediate 5 2(40%) 3(60%)
Adverse 25 20(80%) 5(20%)
Complex Karyotype 14 14(100%) 0(0%)
MLL 7 2(29%) 5(71%)
Other Adverse 4 4(100%) 0(0%)
FLT3 p*=0.537
ITD 15 9(60%) 6(40%)
Mutation 6 2(33%) 4(67%)
ITD+Mutation 1 1(100%) 0(0%)
Negative 61 35(57%) 26(43%)
ND 33 11(33%) 22(67%)
*p value from Fisher-Freeman-Halton exact test.
**Samples were analyzed cytogenetically according to standard methods and
were sub-classified into three sub-groups according to the CALGB cytogenetics
cumulative incidence of relapse classification system [39]. The Fisher-Freeman-
Halton exact test was calculated for the three major groups (favorable,
intermediate, and adverse).
doi:10.1371/journal.pone.0012197.t001
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reagents and conditions recommended by the manufacturer
(Illumina, Inc). The arrays were hybridized under a temperature
gradient program imaged using a BeadArray Reader (Illumina,
Inc). Each methylation data point is represented by fluorescent
signals from the M (methylated, Cy5) and U (unmethylated, Cy3)
alleles. Background intensity, computed from a set of negative
controls, was subtracted from each analytical data point. The ratio
of fluorescent signals was then computed from the two alleles
according to the following formula:
b~Max Cy5,0 ðÞ =Max Cy3,0 ðÞ zMax Cy5,0 ðÞ z100
The b value provides a continuous measure of levels of DNA
methylation in the samples, ranging from 0 in the case of
completely unmethylated sites to 1 in completely methylated sites.
An absolute value is used in the denominator of the formula, as a
compensation for any negative values which may arise from global
background subtraction (i.e.,over subtraction). A constant bias of
100 is added to the denominator to regularize b when both U and
M values are small. (More setailed information could be found on
the GoldenGate Assay for Methylation System User Guide;
Illumina Part No.#11228975)’’. The high reproducibility of the
GoldenGate Methylation Cancer Panel I (mean coefficient of
determination [R
2]=0.99) has been demonstrated elsewhere [16].
Before the methylation data were analyzed, 84 CpGs located on
chromosome X and 11 CpGs showing interlab differential
methylation (i.e. interarray version) were excluded to avoid possible
sources of biological and technical bias. A total of 1410 CpGs from
767 genes underwent further statistical analysis [17]. Whether a
CpG falls within a CpG island or not (non-clustered CpG) has been
defined according to Takai and Jones relaxed criteria [18].
Hierarchical cluster analysis and differential methylation
analysis
Hierarchical clustering was performed using Gene Cluster 3.0
and visualized using Treeview 3.0 (both from http://rana.lbl.gov/
eisen). Selection of differentially methylated CpGs or unmethy-
lated CpGs was based on the presence of a Delta ß value (Dß) of at
least 0.34 between samples and controls [Dß=samples mean ß
value – controls mean ß value] and a false discovery rate (FDR)
below 0.05, calculated using t tests or analysis of variance if more
than two groups were compared. The data were analyzed through
the use of Ingenuity Pathways Analysis (IngenuityH Systems, www.
ingenuity.com). Canonical pathways analysis identified the
pathways from the Ingenuity Pathways Analysis library of
canonical pathways that were most significant to the data set.
The significance of the association between the data set and the
canonical pathway was measured in 2 ways: 1) A ratio of the
number of molecules from the data set that map to the pathway
divided by the total number of molecules that map to the
canonical pathway is displayed. 2) Fisher’s exact test was used to
calculate a p-value determining the probability that the association
between the genes in the dataset and the canonical pathway is
explained by chance alone.
We examined the association between each cluster identified on
the unsupervised analysis and each of the karyotype, the
cytogenetic prognostic group, the F.A.B subtype and the FLT3
status variables using a chi-squared test. Because of the relatively
small sample size and large number of zero cells, we computed p-
value using Monte Carlo simulation, with 500000 replicates,
instead of relying on the asymptotic chi-squared distribution of the
test statistic.
Distribution of aberrant promoter methylation of DBC1
and CDKN2B in an independent AML validation series
Methylation-specific polymerase chain reaction (MSP) analysis
was used to determine the methylation status of the DBC1
(NM_014618) and CDKN2B (NM_078487.2) genes in two
independent experiments for all samples, as previously described
[19]. DNA was extracted using the QIAmp DNA Mini Kit
(Qiagen GmbH, Hilden, Germany) and modified using the
EpiTectH Bisulfite Kit (Qiagen GmbH, Hilden, Germany). Primer
sequences, PCR conditions, and product size are shown in
Document S1. Bisulfite sequencing was performed in 9 samples as
previously described [20]. Primer sequences, designed using the
Methyl Primer Express SoftwareH (Applied Biosystems Inc, Foster
City, CA, USA), are shown in Document S1. At least 10 colonies
of each product were sequenced. CpGs with over 40% positive
clones were considered as abrerrantly methylated.
Identification of DBC1 as a prognostic marker
To build a predictor based on the methylation status of the 115
selected genes with larger variation across the original series, we
used the web tool SignS (http://signs.bioinfo.cnio.es) [21]. To use
this web tool we provided three files: one with the gene
methylation data, another with the survival time, and a third
indicating whether the event was observed or not (the latter being
the censored cases). The method used was based on boosting with
component-wise univariate Cox models. The number of boosting
iterations was selected using cross-validation. For the final results,
the variables (CpGs) with non-zero coefficients at the optimal
number of iterations were selected. These results were validated
using scores from a second final model using the threshold
gradient descent method.
Survival was analyzed using Kaplan-Meier plots and the log-rank
test. Cox proportional hazards models were fitted for multivariate
analysis.Atwo-tailedp,0.05wasconsideredstatisticallysignificant.
SSPSv.15 was used for the statistical analysis.
Aberrant promoter methylation and DBC1 silencing
Expression of DBC1 was analyzed in 25 bone marrow samples,
including both methylated and unmethylated specimens. RNA
was isolated using the MagNa Pure LC mRNA HS kit, automated
on the MagNa Pure robot (Roche Diagnostics GmbH, Mannheim,
Germany). Total RNA was reverse-transcribed using random
hexamer primers with the TaqManH Gold RT-PCR Kit (Applied
Biosystems). Quantitative estimation of the relative DBC1 mRNA
levels was performed by the ABI PRISM 7300 Sequence
Detection Instrument and software (Applied Biosystems) with
specific oligonucleotides and pre-developed TaqMan Assays
(Assay-on-DemandH, Applied Biosystems) following the manufac-
turer’s protocol. The relative quantification of DBC1 levels was
expressed as follows: 2
2[DCt(AML samples)2DCt(CD34+cells)]=2
2DDCt,
where DCt=Ct(DBC1)2Ct(GAPDH) [22]. MSP-positive and MSP-
negative cases were compared using the Mann-Whitney U test.
Results
Methylation profiling of AML
DNA methylation levels were measured in 116 diagnostic AML
samples (Table 1) and 6 control samples (see Material and
Methods) at 1410 loci across the genome. Only the 115 CpGs with
a standard deviation across all samples and controls .0.25 were
selected for an unsupervised hierarchical cluster analysis that
segregated the AML cohort into two main groups (Figure 1A). No
statistically significant association was observed between the
methylation groups and age, sex, F.A.B subtype or FLT3 status
AML Epigenetics
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statistically significant association with specific prognostic cytoge-
netic groups (p,0.001, Fisher-Freeman-Halton exact test) (Table 1).
Group I (58 patients) segregated 80% of the cases from the adverse
cytogenetic prognostic group (cluster 1), 52% of cases from the
intermediate cytogenetic prognostic group (clusters 3 and 4), 45% of
cases with an inv(16) (cluster 2). Group II, with the same number
of cases (n=58), was distributed into 6 distinct smaller clusters,
including thoseassociated withchromosomalrearrangementst(8;21)
(cluster 6), t(15;17) (cluster 9), inv(16) (cluster 8), MLL rearrange-
ments (clusters 11), or normal Karyotypes (cluster 5) (Figure 1A).
The analysis of the distribution of each of the eleven clusters
identified showed for Karyotype, Cytogenetic Group, and F.A.B.
subgroups, a very strong evidence of an unequal distribution among
clusters (p-values for all three variables=2*10
26, the smallest
possible p-value attainable with 500000 simulations). For FLT3, a
moderate evidence of unequal distribution (p-value=0.02) was
found. The distribution of the AML primary cases and the
epigeneticsignature for eachcluster are shown on TablesS1 and S2.
Next, to gain further insight into the importance of these two
main epigenetic signatures, we performed a differential methyla-
tion analysis (see Material and Methods section) to select. among
the 115 probes used for hierarchical clustering, those 35 CpGs that
were differentially methylated (Dß.0,34 & FDR,0.05, t-test) or
unmethylated (Dß,20,34 & FDR,0.05, t-test). We reasoned that
these CpG sites represented those probes with changes on the
methylation status in a large proportion of patients (concordantly
altered probes) (Table S3). Focussing in those 35 selected CpGs,
we observed that, while Group I showed only 7 differentially
methylated CpGs, Group II included 23 differentially methylated
CpGs (located at CpG islands and affecting to 20 genes,) and 10
differentially unmethylated CpGs (six of which were located at
non-clustered CpGs) (Figure 1B). These results indicated aberrant
promoter methylation of CpG islands and hypomethylation of
selected non-clustered CpGs in the Group II AML cases.
The aberrantly methylated genes in Group II included tumor
suppressor genes (HIC1), genes involved in cell cycle control
(DBC1, CDH13, CDKN2B, MOS, and PITX2), development/
differentiation (CDH11, MYOD1, SOX17), and apoptosis (ALOX12,
NEFL). Interestingly, canonical pathway analysis of the 20
aberrantly methylated genes in AML Group II showed significant
involvement of the Wnt/bcatenin signaling pathway through the
aberrant methylation of FRZB, FZD9, and SOX17 (p=0.001,
Fisher exact test & ratio 3/165). These 20 genes were distributed
along chromosomes 2, 4, 6, 7, 8, 9, 11, 14, 16, and 17. Of the total
number of probes on chromosomes 8 and 16 in the array, more
than 10% were represented among our candidate genes. Kaplan-
Meier plots did not reveal significant differences in the overall 5-
year survival between AML Groups I and II (Figure S1).
Methylation status of DBC1 as a predictor of AML
outcome in cases with a normal karyotype at diagnosis
To determine the prognostic value of the methylation status of
specific genes, we used the bioinformatic tool SignS, with the ß
values of the same 115 CpGs that showed a larger variation across
the original series (same as above). When the cases with a normal
karyotype (n=39) were studied, a significant lower overall survival
rate was observed among the patients with aberrant methylation of
two CpGs, DBC1_E204_F and CDKN2B_sec50 (Figure S2).
Conventional Kaplan-Meier analysis confirmed these results
(Figure 2A).
The selected DBC1 and CDKN2B CpGs were studied using MSP
in an independent series of 244 and 151 cases, respectively. Similar
frequencies and distributions to those of the original series were
observed (Table 2). In cases with a normal karyotype, the presence
of a positive methylated allele within the CDKN2B promoter was
not found to be significantly associated with poor outcome in the
validation cohort. In contrast, aberrant promoter methylation of
DBC1 was found to be associated with a significantly worse ten-
year survival (overall survival, p=0.038 and disease-free survival,
p=0.048 by the log-rank test). The estimated median overall
survival was 57 months for the unmethylated group compared
with 15 months for the methylated group. No differences were
observed in relapse rates between patients in the methylated or
unmethylated groups (Figures 2B and 2C). Furthermore, a
statistically significant association was not observed between
aberrant methylation of DBC1 and other important known
prognostic factors in AML harboring a normal karyotype, such
as NPM1 mutations, FLT3 mutational status, and response to
treatment. An even distribution of cases with aberrantly
methylated DBC1 was observed for NPM1 mutations and
treatment response (Table 3). Interestingly, FLT3 aberrations
were two times more prevalent in the methylated DBC1 group and
the presence of both hits was associated with a significantly worse
ten-year overall survival (overall survival, p=0.0075 and disease-
free survival, p=0.0071 by the log-rank test) (Figure S3).
Multivariate proportional-hazard analysis revealed that DBC1
methylation status was not independent of other risk factors
determined to be significant in the model, such as FLT3 mutations,
age, and response to treatment (Table S4).
Finally, we determined the extent of aberrant methylation of
DBC1 by bisulfite sequencing of the genomic region where the
DBC1_E204_F was located. Nine patient’s samples, with a known
methylation status assessed by MSP (positive and negative) at the
DBC1 promoter, were further studied. No densely methylated
CpGs were found in the MSP-negative samples (n=4), whereas all
the analyzed MSP-positive cases (n=5) were found to have a
median of 16 positive clones in the 20 CpGs analyzed (Figure 2D).
Furthermore, we found that aberrant methylation of DBC1 was
associated with reduced expression, as measured by quantitative
PCR. Complete DBC1 silencing was observed in over 90% (17 out
of 18) of the MSP-positive cases and in 35% (6 out of 17) of the
MSP-negative samples (Figure 2E).
Effect of fusion proteins on the epigenetic profiling of
AML
The methylation profile of primary AML samples at diagnosis
suggested a direct interaction between fusion proteins and DNA
Figure 1. Unsupervised Clustering analysis of AML series and differential methylation status at specific CpG islands. A) Thumbnail
overview of the two-way (probes against samples) hierarchical cluster obtained using the complete linkage method and correlation-based distance
metric on 116 AML samples and 6 controls (columns) against 115 probes with variable b values (rows). b values are depicted using a pseudocolor
scale. Samples are color-coded according to the prognostically relevant cytogenetic groups, determined on the basis of conventional chromosome-
banding and fluorescence in situ hybridization analysis. Cluster numbers and methylation groups are indicated. The FLT3 status of the cases is shown.
B) Graphical view of the of 35 selected differentially methylated CpG (red) and differentially unmethylated CpG (blue) loci in primary AML samples,
along with the Db values of the control samples relative to 5 CD34+ selections obtained from cord blood samples. The areas corresponding to a
Db.0.34 and ,20.34 are shaded. The significant probes for each group of samples are indicated.
doi:10.1371/journal.pone.0012197.g001
AML Epigenetics
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in the methylation signature, we studied 20 HSPC samples
expressing the MLL/AF9 (HSPC-MA9) or the core binding factor
(CBF) fusion proteins AML1/ETO or CBFB/MYH11 (HSPC-AE
or HSPC-CM), which have been characterized elsewhere [13].
To define the MLL methylation signature, we selected 144
CpGs that showed an standard deviation across MLL and control
samples .0.25 (Table S5). Unsupervised hierarchical clustering
revealed that primary MLL cases and HSPC-MA9 samples were
easily separated from the healthy control samples, and distinct
methylation signatures were obtained for MLL samples (Figures
S4A and S5B). Forty-one CpGs were differentially methylated
between AML and the control samples (Table S5). Six out of nine
differentially methylated CpGs (all within CpG islands) involving
the DBC1, DIO3, FZD9, CDH13, and MOS genes, and 11 out of 12
differentially unmethylated CpGs (70% non-clustered CpGs)
identified in primary MLL showed the same status in the
HSPC-MA9 samples (Figure 3A and Table S5). Furthermore, a
statistically significant positive correlation between primary MLL
and myeloid HSPC-MA9 samples was observed when comparing
the Dß values at the 115 CpGs with a larger variation across the
original series (Figure 3B). These results indicated that the MLL/
AF9 fusion protein drives the methylation signature harbored by
the primary AML MLL cases.
To establish the role of the lymphoid/myeloid lineage
commitment in the methylation signature, we analyzed a set of
13 primary ALL samples. Unsupervised hierarchical clustering
revealed that primary MLL and HSPC-MA9 samples had a
methylation signature that was different from that of primary ALL
samples harboring the TEL/AML1 or BCR/ABL fusion genes
(Figure S4B). Five times more differentially methylated CpGs
across the genome were observed in the lymphoid MLL than in
the myeloid MLL samples (Table S5) and the DBC1, DIO3, FZD9,
and MOS genes were identified as differentially methylated CpGs
in all the MLL samples. These results suggest an important
contribution of DNA methylation to cell lineage commitment with
a non-random epigenomic signature in MLL.
To determine the CBF methylation signature, we selected 110
CpGs with an standard deviation across CBF samples and controls
.0.25. Unsupervised hierarchical clustering revealed that HSPC-
CBF samples segregated with the healthy control samples (Figure
S5A), and we did not identify a common signature between
Table 2. Distribution of aberrant methylation of DBC1 and CDKN2B promoters in two independent AML series.
DBC1* CDKN2B*
Original Set Illumina Array Validation Set MSP Analysis
Original Set Illumina
Array
Validation Set MSP
Analysis
N Methylated N Methylated N Methylated N Methylated
Favorable Group
t(15;17) 9 9 (100%) 19 16 (84%) 9 5 (55.5%) 7 3 (42%)
inv(16) 11 9 (82%) 9 5 (56%) 11 4 (36.4%) 0 -
t(8;21) 10 10 (100%) 12 8 (66%) 10 7 (70%) 3 2 (66%)
Intermediate Group
Normal Karyotype 41 21 (51.2%) 111 54 (49%) 41 15 (36.6%) 99 42 (42%)
Trisomy 8 7 6 (86%) 12 6 (50%) 7 2 (28.6%) 3 1 (33%)
Other Intermediate 13 9 (69%) 21 12 (52%) 13 4 (31%) 10 3 (30%)
Adverse Group
Complex Karyotype 14 1 (7%)** 16 11 (69%) 14 3 (21.4%) 7 2 (29%)
MLL 7 7 (100%)*** 2 0 (0%) 7 1 (14%) 2 1 (50%)
Other Adverse 4 1 (25%) 7 1 (14%) 4 1 (25%) 2 1 (50%)
Other - - 35 15 (42%) - - 18 6 (33%)
Total 116 71 (61%) 244 128 (52%) 116 43 (37%) 151 61 (40%)
MLL, mixed lineage leukemia; MSP, methylation-specific polymerase chain reaction; N, number of cases. (*)The frequencies of methylated DBC1 and CDKN2B in both sets
of samples were compared in all categories using the Fisher exact test. There were no statistical differences in the frequencies, except for (**) p=0.001 and (***) p=0.28.
Other: Cases with no available cytogenetic data.
doi:10.1371/journal.pone.0012197.t002
Figure 2. The methylation status of DBC1, influence in survival parameters and sequencing validation. A) Kaplan-Meier plots for the 39
patients with available clinical data from the original series and a normal karyotype at diagnosis, stratified by b values at the DBC1_E204_F and
CDKN2_seq50 probes (a b value .0.5 was considered as positively methylated). B) Kaplan-Meier plots and DFS and RFS curves of the validation series,
considering only patients with a normal karyotype and available clinical data, stratified by the methylation status (analyzed by MSP) of the DBC1 and
CDKN2B promoter. C) Examples of the MSP analysis of the DBC1 gene. A visible PCR product in lane U indicates the presence of unmethylated DBC1;a
visible product in lane M indicates the presence of methylated DBC1. CpGenome Universal Methylated DNA (Intergen, New York, NY, USA) was used
as a positive control for methylated alleles. DNA from bone marrow donors was used as a negative control for methylated genes. Water controls for
the PCR reaction are also shown. Samples AML1, AML2, AML3, AML4, and AML5 were methylation-positive, whereas all the others were methylation-
negative. D) Status of 20 CpGs in the DBC1 gene assessed by bisulfite genomic sequencing analysis on 9 AML samples. Primer design for MSP (black
arrows) and bisulfite sequencing (gray arrows) is indicated. The green bar above the diagram of the DBC1 CpG island indicates the location of the
probe used in the methylation arrays. Black squares, methylated CpG; white squares, unmethylated CpG dinucleotides. E) Box plot of the DBC1
relative transcript expression measured by quantitative PCR. MSP-positive and negative cases were compared using the Mann-Whitney U test.
doi:10.1371/journal.pone.0012197.g002
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selected as differentially methylated (Table S6), primary CBF cases
showed two to three times more differentially methylated CpGs
than HSPC-CBF samples, and over 95% of the differentially
methylated CpGs on the primary CBF cases were located at CpG
islands compared with only half of the differentially methylated
CpGs selected for the HSPC-CBF samples (Figure 3C). Further-
more, the CBF methylation signature that includes the 15
differentially methylated CpGs and 9 differentially unmethylated
CpGs identified on primary CBF samples was not present in
HSPC-CBF samples (Table S6). Finally, when the Dß values at the
115 CpGs were compared with larger variations across the
original series, a significant positive correlation (R
2.0.83) between
the t(8;21) and inv(16) primary AML patients and an absence of
correlation between primary samples and their respective HSPC
models was observed (Figure 3D). These data confirmed the
presence of a partially common methylation signature between
cases of primary CBF leukemia and demonstrated that these fusion
proteins alone are not capable of recapitulating the methylation
signature observed in their respective primary AML samples.
Discussion
The present report is a systematic study of DNA methylation
patterns on adult de novo AML. Our unsupervised clustering
analysis of 116 patients revealed that distinct epigenetic signatures
could be identified based on a limited number of genes. Recent
reports, using different epigenomic approaches with a much larger
number of CpGs [8,9], also defined epigenetic profiles for cases
harboring balanced translocations such as t(8;21), inv(16), t(15;17),
or MLL rearrangements. Nevertheless, our data showed that most
of these cases with chromosome rearrangements were clustered in
a large group (Group II) that shows abundant and common
epigenetic modifications on CpG islands and hypomethylation of
selected non-clustered CpGs. Within Group II, we identified a
subset of 20 genes conforming an epigenetic signature common to
AML with fusion proteins and a subset of AML cases from the
intermediate cytogenetic prognostic subgroup. Furthermore, the
pathway analysis of these aberrantly methylated genes showed a
significant involvement of the Wnt signaling pathway. These
results are consistent with our recent studies and reveal a
Table 3. Distribution of DBC1 promoter methylation among patients with a normal karyotype at diagnosis.
Discovery Set
GoldenGate Methylation Validation Set
Cancer Panel I MSP Analysis
N UNMET MET p value
# N UNMET MET p value
#
FLT3-ITD 38 4/18
* 8/20 NS 90 7/44
* 14/46
* NS
NPM1 - - - - 67 15/33
* 16/34
* NS
Gender 39 NS 111 NS
N Male 8/19 9/20 28/57 26/54
N Female 11/19 11/20 29/57 28/54
Age 39 NS 111 NS
N ,60 years-old 4/19 9/20 37/57 29/54
N .60 years-old 15/19 11/20 20/57 25/54
WBC 39 NS 111 NS
N ,10610
9/L 6/19 7/20 28/57 28/54
N .10610
9/L 13/19 13/20 29/57 26/54
FAB Sub-type 39 NS 111 NS
N M0 0/19 1/20 1/57 5/54
N M1 5/19 5/20 16/57 14/54
N M2 5/19 4/20 16/57 15/54
N M3 0/19 0/20 0/57 0/54
N M4 6/19 3/20 13/57 10/54
N M5 3/19 7/20 7/57 4/54
N M6 0/19 0/20 1/57 3/54
N M7 0/19 0/20 0/57 1/54
N Unclassified 0/19 0/20 3/57 2/54
Treatment Response -- 1 0 1 N S
N Complete Remission - - - 38/48 37/53
N Resistance - - 6/48 9/53
N Death - - 4/48 7/53
MSP, methylation-specific polymerase chain reaction; NS, non-significant; MET, methylated; UNMET, unmethylated.
#p values were calculated using Fisher’s exact test. p,0.05 was considered statistically significant.
*The mutational status of FLT3 and NPM1 was not available for all patients.
doi:10.1371/journal.pone.0012197.t003
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PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12197significant role of the epigenetic modifications of Wnt antagonists
in the pathogenesis of AML [23,24]. On the other hand, cases
harboring complex karyotypes clustered within Group I AML,
which did not show a hypermethylated signature, supporting the
hypothesis put forward by Koeger et al. of a negative correlation
between epigenetic and chromosomal instability [7].
Our results, along with previous studies, suggested a link
between genetic/chromosome rearrangements and the induction
of aberrant DNA methylation [8,9,11,25]. We previously showed
that the overexpression of the MLL/AF9 fusion protein on
HSPC induced acute myeloid, lymphoid, or mixed-lineage
leukemia in immunodeficient mice, and that these transformed
HSPC could be lineage-directed by altering either the growth
factors or the recipient mouse strain [13]. Using this leukemic
HSPC model, we demonstrated that MLL/AF9 recapitulated the
epigenetic profile observed in the MLL-positive patients, as has
been shown in mice models with other genetic insults [25], thus
supporting a direct role for MLL fusion proteins in the down-
regulation of target genes by DNA methylation [26]. However,
the mechanisms underlying this signature have yet to be
explored. Furthermore, the observed ALL MLL methylation
profile included a significantly higher number of aberrantly
methylated CpGs than the AML cases. These results support the
essential role of DNA methylation in the plasticity of the
hematopoietic system [27,28], suggesting interplay between
transcription factors downstream of cytokine receptors and the
DNA methylation machinery.
Conversely, AML1/ETO and CBPb/MYH11 overexpression on
HSPC failed to reproduce the epigenetic signature observed in the
primary patients, suggesting that these two CBF fusion proteins
are insufficient to target DNA methylation to specific sites, as they
are not capable of inducing a fully transformed phenotype [29,30].
These results suggest that, either longer periods of time (more than
12 weeks) are needed to induce the epigenetic modifications or
that these fusion proteins do not have a direct impact on the DNA
methylation profile (as is shown to happen in the HSPC model).
Further research exploring the mechanisms driving the specific
epigenetic signature of the different cytogenetic subgroups seems
warranted.
In addition, another major objective of our study was to
determine whether patterns of DNA methylation signature could
be used to improve patient prognostification, mainly among the
abundant normal karyotype group of cases. As other [8] we were
not able to correlate the presence of a methylation signature with
different clinical outcomes among normal karyotype cases, as it
has been previously reported using larger number of CpGs [9].
However, using specific biomarkers, differences in overall survival
in patients with AML have been revealed by analysis of concurrent
aberrant methylation of specific genes, such as ESR1, CDKN2B/
p15, and IGSF4 [31]. Using the SignS web tool, we were able to
identify the methylation status of the deleted in bladder cancer 1
(DBC1) and the cyclin-dependent kinase inhibitor 2B (CDKN2B/
p15) as predictors of overall survival in the AML subgroup with a
normal karyotype. Only aberrant methylation of the DBC1
promoter was observed to have statistically significant prognostic
value among cases with a normal karyotype in an independent
case series. DBC1 and CDKN2B have been shown to have tumor-
suppressor activity through the negative regulation of G1 cell cycle
progression, and their loss of function has been associated with an
advantage in proliferation, growth, and malignant transformation
[32,33]. Our results suggest that the clinical importance of
CDKN2B methylation in AML is still controversial [34].
Hypermethylation associated with reversible epigenetic silenc-
ing of DBC1 has been reported in hematological disorders
[19,35,36] and in solid tumors [37,38]. This silencing mechanism
has been postulated as an early and age-independent event in the
development of malignancy [35,38]. We identified aberrant
methylation of DBC1, located at 9q33.1, as an adverse prognostic
marker in the AML subgroup with a normal karyotype.
Furthermore, when this epigenetic event is combined with FLT3
status, it constitutes a unique and powerful predictor of clinical
outcome within AML cases with a normal karyotype. However,
under current therapeutic regimens, this epigenetic marker does
not retain its independence in the multivariate analysis. The
identification of patients with aberrant DNA methylation patterns
that can predict survival will be essential in future designs of
clinical trials with demethylating agents.
In conclusion, comprehensive epigenetic profiling of AML
provides relevant biological information and new clinical markers
that should be integrated in the design of clinical trials with
demethylating agents.
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Figure 3. Comparison of the methylation patterns of primary samples and hematopoietic stem cells/progenitor cells. A) Graphical
view of the 41 selected differentially methylated CpGs (bold) and differentially unmethylated CpGs (italics) in primary MLL AML samples and in the
AML HSPC-MA9 samples. The area corresponding to a Db.0.34 or ,20.34 is shaded. The figure shows whether the selected CpG is included (Y) or
not (N) in a CpG island. B) Scatter plot of the Db values of the 115 CpGs selected to define the AML methylation signatures. C) Graphical view of the
81 selected differentially methylated CpGs (bold) and differentially unmethylated CpGs (italics) in primary AML samples harboring t(8;21) or inv(16)
and in the HSPC-AE and HSPC-CM samples. The areas corresponding to a Db.0.34 and ,20.34 are shaded. The figure shows whether the selected
CpG is included (Y) or not (N) in a CpG island. D) Scatter plots of the Db values of the 115 CpGs selected to define the AML methylation signatures.
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Figure S2 A DNA Methylation Classifier to predict Clinical
Outcome in the AML cases included on the intermediate
cytogenetic subgroup or in the Normal karyotype cases. Results
obtained using the Beta values of the 115 CpGs with a larger
variation across the original series, the SignS Web tool for gene
selection and signature finding, build a predictor model of overall
survival based on the methylation status of two CpGs,
DBC1_E204_F and CDKN2B_sec50. Survival curves comparing
low-score and high-score models from final models, with those two
probes, using boosting of a component-wise Cox model (A and B)
and the threshold gradient descent method (B and C) are shown.
Found at: doi:10.1371/journal.pone.0012197.s009 (3.01 MB TIF)
Figure S3 Kaplan-Meier overall survival and disease-free
survival curves for patients with available clinical data and a
normal karyotype at diagnosis from the validation series, stratified
by MSP result and the DBC1 gene and the FLT3 status.
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Figure S4 A) Unsupervised hierarchical clustering by applying
the complete linkage method and uncentered based distance
metric for 7 AML-primary MLL cases, 3 primary ALL-MLL
cases, 10 HSPC-MA9 (5 myeloid and 5 lymphoid), and 11 controls
(4 bone marrow, 2 selected CD34+, and 5 CB) in the 144 probes
selected by filtering with a standard deviation over 0.25 across all
samples. B) Unsupervised hierarchical clustering by applying the
complete linkage method and uncentered based distance metric
for 13 ALL primary cases (3 MLL cases, 5 TEL/AML1 cases, and
5 BCR/ABL cases), 5 lymphoid HSPC-MA9, and 11 controls (4
bone marrow, 2 selected CD34+ samples, and 5 cultured cord
blood samples), using 51 probes with a standard deviation over
0.25 across all the samples.
Found at: doi:10.1371/journal.pone.0012197.s011 (6.01 MB TIF)
Figure S5 A) Unsupervised hierarchical clustering with the
complete linkage method and euclidean-based distance metric of
the primary CBF leukemia cases, HSPC-CBF and controls (bone
marrow and cord blood). B) Unsupervised hierarchical clustering
of the primary AML MLL leukemia cases, myeloid HSPC-MA9
and controls (bone marrow and cord blood) performed with 90
selected probes after filtering with an SD.0.25.
Found at: doi:10.1371/journal.pone.0012197.s012 (6.01 MB TIF)
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